Recombinant Human SerpinC1 / AntithrombinIII / ATIII Protein (His tag)
Fusion tag
C-His
Mol Mass
50.5 kDa
Conjugation
histidine
AP Mol Mass
55-60 kDa
Accession
NP_000479.1
Group
recombinants
Expressed Host
HEK293 Cells
Sequence
Met 1-Lys 464
Source
Recombinants or rec. proteins
Purity
＞95 % as determined by SDS-PAGE
Formulation
Lyophilized from sterile PBS, pH 7.4
Synonym
AT3;AT3D;ATIII;MGC22579;SerpinC1;THPH7
Endotoxin
＜1.0 EU per µg as determined by the LAL method
Activity
Measured by its ability to inhibit thrombin (Sigma, Catalog # T4648)cleavage of a fluorogenic peptide substrate Boc-VPR-AMC.The IC50 value is < 5 nM.
Stability and Storage
Samples are stable for up to twelve months from date of receipt at -70℃.Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Properties
Human proteins, cDNA and human recombinants are used in human reactive ELISA kits and to produce anti-human mono and polyclonal antibodies. Modern humans (Homo sapiens, primarily ssp. Homo sapiens sapiens). Depending on the epitopes used human ELISA kits can be cross reactive to many other species. Mainly analyzed are human serum, plasma, urine, saliva, human cell culture supernatants and biological samples.
Background
SerpinC1, also known as antithrombin III (AT III), is a member of the serpin superfamily of serine protease inhibitors, and has been found to be a marker for disseminated intravascular coagulation (DIC) and to be of prognostic significance in septic patients. SerpinC1 synthesized in the liver is the principal plasma serpin of blood coagulation proteases and inhibits thrombin and other factors such as Xa by the formation of covalently linked complexes. Thus it is one of the most important coagulation inhibitors and the fundamental enzyme for the therapeutical action of heparin. In common with SerpinA5 and D1, the inhibitory activity of SerpinC1 undergoes a dramatic increase in the presence of heparin and other glycosaminoglycans. ATIII mediates the promotion of prostaglandin release, an inhibitor of leucocyte activation and downregulator of many proinflammatory cytokines. Antithrombin III exerts anti-inflammatory properties in addition to its anti-coagulative mechanisms. In animal models of sepsis, ATIII affected cytokine plasma concentrations with a decrease of pro-inflammatory cytokines. The deficiency or functional abnormality of ATIII may result in an increased risk of thromboembolic disease, such as deep vein thrombosis and pulmonary embolism. In addition, it has been reported that SerpinC1 can alter or influence inflammatory processes via inhibition of NF-κB activation or actin polymerization.